Encompass Health (EHC) Stock Still Looks Undervalued Following Its 107% Run
Encompass Health stock has more than doubled over the past five years, yet current checks suggest the shares may still trade below an intrinsic value estimate built from a Discounted Cash Flow (DCF) model and supported by market multiples that also screen as undervalued.
- Encompass Health has returned 107.5% over five years, which makes the current valuation especially important for anyone considering the stock today.
- Expectations for continued steady cash generation from its rehabilitation hospital network can support the valuation, while any pressure on reimbursement rates or operating costs may limit how much investors are willing to pay for that cash flow profile.
- On Simply Wall St's broader checks, Encompass Health looks undervalued on 4 of 6 measures, which is a mixed picture rather than a straightforward deep value case, as shown by its 4 out of 6 valuation score.
The stock's next move may depend on whether the market closes the gap to this intrinsic value estimate or keeps Encompass Health trading at a discount.
Find out why Encompass Health's -1.3% return over the last year is lagging behind its peers.
Is Encompass Health Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what Encompass Health is worth based on the cash it is expected to generate for shareholders. The latest twelve month free cash flow is about $435 million, and the model assumes these cash flows continue growing rather than shrinking. On that basis, the 2 Stage Free Cash Flow to Equity approach indicates an intrinsic value of about $143 per share.
Compared with the current share price, that intrinsic value suggests the stock trades at a 15.7% discount. For readers, this points to a business where steady cash generation from Encompass Health’s rehabilitation hospitals has a larger influence in the model than aggressive growth forecasts or one off events.
On this DCF view, Encompass Health stock currently appears undervalued.
Our Discounted Cash Flow (DCF) analysis suggests Encompass Health is undervalued by 15.7%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.
Is Encompass Health a Bargain on Earnings?
P/E metrics suit Encompass Health because earnings are a key focus for mature healthcare providers. The stock trades on a P/E of about 19.8x, compared with a Healthcare sector average of roughly 25.2x and a peer group average of about 17.4x. That places Encompass Health at a discount to the broader sector, although it is not the cheapest option among more direct peers.
The fair P/E ratio for Encompass Health is estimated at about 24.9x. This is higher than the current 19.8x level, which points to a gap between what investors are paying today and what the tailored model suggests could be reasonable given the company’s profile. For readers comparing tools, this aligns with the earlier DCF work, since both approaches indicate the stock may not be pricing in the full earnings power implied by these models.
On this P/E analysis, Encompass Health stock appears undervalued relative to its modelled fair multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Encompass Health Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Encompass Health pick up where the valuation work stops and set out the assumptions on growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today's price. Instead of providing a single ratio or model output, these narratives explain the future that figure relies on so you can judge over time whether Encompass Health's actual progress supports it. They are available on Simply Wall St's Community page.
Community views on Encompass Health are split, with one camp focused on capacity driven upside and the other on execution and competitive risks.
Bull case: 17% undervalued
"The surge in the 65-plus population and persistent undersupply of inpatient rehabilitation beds are driving high and still unmet demand for Encompass Health's core services..."
Read the full Bull Case to see why Encompass Health could be undervalued
Bear case: 22% overvalued
"The accelerating industry shift toward value-based care and outpatient/home-based rehabilitation models threatens the long-term relevance of inpatient rehabilitation facilities..."
Read the full Bear Case to see why Encompass Health could be overvalued
Do you think there's more to the story for Encompass Health? Head over to our Community to see what others are saying!
The Bottom Line
Encompass Health screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple work, although the broader checks look mixed rather than emphatically cheap. The investment case now turns on whether cash generation and margins from its rehabilitation hospitals prove resilient enough for the market to close some of that discount. The key question for readers is whether reimbursement pressure and rising costs cap the P/E and keep the stock stuck on a discount, or whether steady execution convinces investors to pay closer to the intrinsic value implied by these models.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com